Viridian Therapeutics Stock Price To Earnings To Growth
| 0K1R Stock | 18.09 1.09 5.68% |
Viridian Therapeutics fundamentals help investors to digest information that contributes to Viridian Therapeutics' financial success or failures. It also enables traders to predict the movement of Viridian Stock. The fundamental analysis module provides a way to measure Viridian Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Viridian Therapeutics stock.
Viridian | Price To Earnings To Growth |
Viridian Therapeutics Company Price To Earnings To Growth Analysis
Viridian Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Viridian Therapeutics has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Commercial Services & Supplies sector and about the same as Industrials (which currently averages 0.0) industry. The price to earnings to growth for all United Kingdom stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Comparator Now
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account |
| All Next | Launch Module |
Viridian Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (970.70) % | ||||
| Current Valuation | 969.97 M | ||||
| Shares Outstanding | 30.84 M | ||||
| Shares Owned By Institutions | 100.00 % | ||||
| Price To Sales | 11.50 X | ||||
| Revenue | 314 K | ||||
| Gross Profit | (99.12 M) | ||||
| EBITDA | (234.56 M) | ||||
| Net Income | (237.73 M) | ||||
| Total Debt | 21.05 M | ||||
| Book Value Per Share | 6.55 X | ||||
| Cash Flow From Operations | (184.17 M) | ||||
| Earnings Per Share | (5.14) X | ||||
| Number Of Employees | 94 | ||||
| Beta | 1.11 | ||||
| Market Capitalization | 2.84 T | ||||
| Total Asset | 490.42 M | ||||
| Retained Earnings | (725.91 M) | ||||
| Net Asset | 490.42 M |
About Viridian Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Viridian Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viridian Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viridian Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viridian Stock Analysis
When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.